hipaa – how will the regulations impact research?

Post on 25-Feb-2016

48 Views

Category:

Documents

0 Downloads

Preview:

Click to see full reader

DESCRIPTION

HIPAA – How Will the Regulations Impact Research?. What is HIPAA?. Health Insurance Portability and Accountability Act of 1996 (Privacy Rule) November 1999 – DHHS proposed regulations December 2000 – Final Rule published August 2002 – New Final Rule published - PowerPoint PPT Presentation

TRANSCRIPT

HIPAA – How Will the Regulations Impact

Research?

What is HIPAA?Health Insurance Portability and Accountability

Act of 1996 (Privacy Rule)

– November 1999 – DHHS proposed regulations– December 2000 – Final Rule published– August 2002 – New Final Rule published– December 2002 – Guidance Document published– Date of Compliance – APRIL 14, 2003

Covered Entities

Health Plans (insurers and payors) Health Care Providers (VUMC) Health Care Clearinghouses (billing

services)

Privacy Rule Protects:

Individually Identifiable Health Information is defined as any information collected from an individual (including demographics) that is:

• created or received by a health care provider, health plan, employer, and/or health care clearinghouse

• relates to the past, present or future:– physical or mental health or condition of an individual, – the provision of health care to an individual; or – payment for the provision of health care to an individual;

and– identifies the individual and/or there is reasonable basis to

believe that the information can be used to identify the individual. (45 CFR 160.103)

Identifying Data Elements• Names• Addresses• Dates• Phone Numbers• Fax Numbers• Social Security Numbers• Medical Record Number• Health Plan Numbers• Account Numbers• Certificate/License

Numbers

• VIN/License Plate Numbers• Device Identifiers• Names of Relatives• Web URLs• IP addresses• Biometric Identifiers• Photographs and

comparable images• Any other unique identifying

number, characteristic, or code

HIPAA Terms• PHI – Protected Health Information• Use – data accessed and shared within the

covered entity• Disclosure – the providing of data outside of the

covered entity, not including Business Associates• Authorization – permission provided by the

patient or legal representative to use or disclose the individual’s PHI

• Limited Data Set – group of data that is de-identified except for geographic location and dates

• Data Use Agreement – document used to create and disclose a Limited Data Set

• Designated Record Set – The part of the medical record used for patient care/treatment

• Minimum Necessary Standard – under certain conditions the covered entity must limit the access to PHI

• Accounting of Disclosures – under certain conditions the covered entity must track disclosures of PHI, such as waiver of authorization

HIPAA Terms Continued

How to Fit HIPAA into your Research?

How to Use or Disclose PHI for Research Purposes

• De-identified data• Limited Data Set• Authorization • Waiver of Authorization

How to use or disclose PHI for research purposes (continued)

• De-identification – Remove all 18 identifiers; or– Statistical Certification – the information

may be considered de-identified, if an independent, qualified statistician:

a. Determines that the risk of re-identification of the data, alone or in combination with other data, is very small; and

b. Documents the methods and results by which the health information is de-identified, and the expert makes his/her determination of risk. Note: the expert may not be the researcher or anyone directly involved in the research study.

• Limit Data Set (LDS)– Allows access to PHI, with limited identifiable

data elements, without an authorization or waiver of authorization

– Requires a Data Use Agreement – Limited Data Set may include:

– Dates– Geographic information (not street address)– Other unique identifying numbers, characteristics, or

codes that are not expressly excluded

How to use or disclose PHI for research purposes (continued)

What is a Data Use Agreement?• The investigator must agree to the following:

– Not to use or disclose the LDS for any purpose other than the research project or as required by law.

– To use appropriate safeguards to prevent use or disclosure of the LDS other than as provided for by the agreement.

– To report to VUMC any use or disclosure of the LDS not provided for by this agreement, of which he/she becomes aware, including without limitation, any disclosure of PHI to an unauthorized subcontractor.

– To ensure that any agent, including a subcontractor, to whom he/she provides the LDS, agrees to the same restrictions and conditions that applies through the agreement to the Data Recipient with respect to such information.

– Not to identify the information contained in the LDS or contact the individual.

• Authorization– Participant provides authorization to use/disclose

PHI as part of the informed consent process. MUST include the following elements:

• Specific description of the information to be used/disclosed

• Who may use or disclose• To whom the PHI will be disclosed• Why the use or disclosure is being made (each

purpose)• Statement of how long the use or disclosure will

continue

How to use or disclose PHI for research purposes (continued)

• Notice that authorization may be revoked • Notice that the information may be disclosed to

others not subject to the Privacy Rule• Notice that the covered entity (VUMC) may or

may not condition treatment or payment on the individual’s signature

• Individual’s signature and date

Authorization elements continued:

• Waiver of Authorization– To be granted by the IRB and must meet the

following criteria:• The use or disclosure of PHI involves no more

than minimal risk to the privacy of the individual.

• The PI must provide a plan to protect identifiers, a plan to destroy the identifiers as soon as possible, and a statement that the information will not be disclosed.

• The PI should provide justification as to why the research cannot be done without the waiver.

How to use or disclose PHI for research purposes (continued)

• The PI should provide justification as to why the research cannot be done without the PHI.

• The PI must provide a written assurance to the IRB that the PHI will not be re-used or disclosed except

– As required by law,– For authorized oversight of the research, or– For other research that has been reviewed

and approved by the IRB with specific approval regarding access to this PHI.

How to use or disclose PHI for research purposes (continued)

Minimum Necessary Standard• A covered entity (VUMC) must try to limit the use or

disclosure of PHI to the minimum necessary to achieve the research purpose.

• This standard applies to the following:– Research pursuant to a waiver– Use/disclosure of decedent’s PHI– Uses preparatory to research– Limited Data Sets

• Minimum Necessary Standard does not apply to the following:– Treatment disclosures or requests– Use or disclosure made with an authorization– Disclosures to the individual– Disclosures to DHHS for compliance– Disclosures required by law

Accounting of Disclosures• Patients have the right to request an

accounting of disclosures of their PHI for past six years.

• Applies to disclosure of PHI pursuant to a waiver of authorization, disclosures required by law, and for public health purposes.

• Does not apply to disclosures pursuant to an authorization or to limited data set.

• The Privacy Office, not the IRB, will maintain a centralized database to track disclosures. This tracking requirement is the responsibility of the PI in conjunction with the Privacy Office.

Common

Rule

Privacy Rule

Where the Common Rule (45 CFR 46) and the Privacy Rule (45 CFR 160 & 164) disagree, the IRB must act in

the best interest of protection of human subjects and follow the

regulation that is more restrictive.

What does not require IRB review?

• Preparatory to Research – defined as any action taken, where access to

PHI is required, for assessing the research question/hypothesis such as accessing medical records or querying of databases to prepare a research protocol.

• The use or disclosure of the PHI is sought solely for the purpose of preparing a research protocol.

• The PHI will not be removed from the covered entity (VUMC).

• This PHI is necessary for the purpose of a research study.

• Research on Decedents– Researchers may use and disclose a

decedent’s PHI for research purposes without IRB review.

– The following criteria must be met in the form of a statement to the covered entity (VUMC):

• The use will be solely for research on the PHI of a decedent.

• The PHI sought is necessary for the purposes of the research.

• The researcher has documentation of the death of the individual about whom information is being sought.

What does not require IRB review?(Continued)

How do we get ready for HIPAA?

Transition PeriodApril 14, 2003

IRB Approval

Planned enrollment of subjects

Planned research assessment period

INFORMED CONSENT DOCUMENTS GRANDFATHEREDHIPAA AUTHORIZATION RIDER IS NOT NEEDED

Transition PeriodApril 14, 2003

IRB Approval

Planned enrollment of subjects

Planned research assessment period

Informed consent documents -

GRANDFATHEREDConsent form(s) need HIPAA Authorization Language

(Rider)

Transition PeriodApril 14, 2003

IRB Approval

Planned enrollment of subjects BUT the IRB has granted a WAIVER OF CONSENT

Planned research assessment period

Waiver of Authorization grandfathered and no action needed.

Transition PeriodApril 14, 2003

IRB Approval

Planned enrollment of subjects

Planned research assessment period

NEW Consent form(s) with HIPAA Authorization Language incorporated with

Confidentiality Language

Transition PeriodApril 14, 2003

IRB Approval

Planned enrollment of subjects AND the study meets the criteria for Exempt under 45 CFR 46.101 category (b) 4.

Planned research assessment period

Complete Affirmation/Data Set Agreement to obtain aLimited Data Set – This is included in the Exempt Application.

Transition PeriodApril 14, 2003

IRB Approval

Planned enrollment of subjects BUT the IRB has granted a WAIVER OF CONSENT

Planned research assessment period

Waiver of Authorization criteria must also be met and approved.This is a combined form currently available on the web.

Proposal

Does this proposal

involve the creating, using, and/or

disclosing of PHI?

Can theresearch be completed

using a LimitedData Set?

yes

PI should complete a

Data Use Agreementwith Affirmation

Statements.

yes

Waiver grantedPI must trackdisclosures

and minimum necessary applies.

yes

HIPAA DoesNot Applyno

Does the proposal

meet HIPAAcriteria for Waiver of

Authorization?no

PI must obtainAuthorization

from the participant.

no

Decision Path

What is the IRB currently doing to prepare for HIPAA?

• The IRB forms and template language are updated and on the website.

• Currently approved studies that will be enrolling beyond April 14, 2003 must have an authorization rider attached to the consent document. Template language for the HIPAA authorization rider is approved and on the website.

• New studies should choose the Confidentiality and Privacy of Health Information language in the template and modify to include study specific information.

VU Institutional Review Board is serving as the Privacy Board for Research for the VUMC Covered Entity.

We are NOT serving as the Privacy Board for Research for institutions outside the Covered Entity (VUMC).

These institutions will need their own authorization language and will be responsible for submission as an amendment, only if VU IRB is serving as the IRB of record or coordinating center.

Sponsors are generally NOT covered entities. The IRB will not be incorporating sponsor’s language in the authorization for patients at VUMC.

The VU IRB is not serving as the Privacy Board for Research for the VAMC.

POINTS to REMEMBER

HIPAA IS COMING!HIPAA IS COMING!Compliance Date:APRIL 14, 2003

Questions?

Additional Training Opportunities

March 24, 2003 Preston Research Building, Room 206

1:30pm - 2:30pm

March 31, 2003

2209 Medical Center North

11:00am-12:00pm

top related